Sun Pharma presented promising data on utreglutide (GL0034) at ObesityWeek® 2025 and the American Heart Association 2025 Scientific Sessions. Studies reveal significant weight loss, improved metabolic markers, and reduced liver fat in individuals with obesity and related conditions. These findings support further clinical investigation of utreglutide as a potential therapy.
Utreglutide Data at ObesityWeek® 2025
Sun Pharma presented two posters on utreglutide at ObesityWeek® 2025, highlighting its impact on weight and metabolic health. In individuals with obesity and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), thirteen weeks of utreglutide dosing led to a significant 6.8% reduction in body weight and waist circumference at week 14. Another study showed that ten weeks of once-weekly utreglutide dosing in overweight and obese individuals resulted in a 6.8% body weight loss, along with reductions in total cholesterol (TC) and LDL of approximately 10%, particularly in those with higher baseline values.
The research demonstrated that utreglutide was well-tolerated, with gastrointestinal issues being the most common adverse events.
American Heart Association Presentation
At the American Heart Association 2025 Scientific Sessions, Sun Pharma shared data from a Phase 1b/2a study of GL0034 in post-menopausal females with obesity. The results showed that once-weekly utreglutide led to an 8% weight loss at week 14, and reduced liver fat content, alongside lower blood pressure. These results came from evaluating subcutaneous utreglutide in post-menopausal women with obesity and MAFLD. The data highlighted meaningful weight loss and waist circumference reduction, with a notable proportion achieving clinically significant outcomes. Improvements included improved systolic blood pressure, reduced liver fat, and favorable changes in biomarkers linked to fibrosis and insulin sensitivity, as well as lower serum uric acid levels.
Once weekly utreglutide dosing for 13 weeks was well tolerated in post-menopausal female participants with obesity and MAFLD.
Source: BSE
